CRISPR Therapeutics

CRSPNasdaq Switzerland Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$5.175 B

$53.52 +3.64%

Close of 7 Aug 2026

Revenue

$3.51M

#3355 by revenue

Earnings

-$581.6M

Loss-making

Shares outstanding

96,692,653

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#21CG OncologyCGON$6.62B
#22Scholar RockSRRK$6.34B
#23CRISPR TherapeuticsCRSP$5.17B
#24Adaptive BiotechnologiesADPT$3.98B
#25Denali TherapeuticsDNLI$3.94B

Where these numbers come from

Share counts and financials for CRISPR Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.